Amicus Therapeutics, Inc. — Earnings Quality Grade F
FOLD · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 66 days, change -3 days YoY
AR growth 14.1% vs revenue growth 20.0%
Revenue 20.0%, CFFO 197.8%. Cash follows revenue
Expense Quality
Inventory growth 92.6% exceeds COGS 37.8%
CapEx growth -7.2% vs revenue 20.0%. Normal
SG&A/Gross Profit = 68.3%. Normal
Gross margin 88.5%, change -1.5pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF $0.0B, FCF/NI = -1.10
Accruals ratio = -6.3%. Low accruals
Cash $0.3B covers 66% of debt $0.4B
Balance Sheet Health
Goodwill+Intangibles $0.2B = 77% of equity. Over 50%
Debt/EBITDA = 8.2x (>4x). Interest coverage = 0.7x (<2x). Financial stress
Other assets 0.7% vs revenue 20.0%. Normal
Write-offs normal
Acquisition Risk
FCF after acquisitions negative for 2/3 years
Goodwill+Intangibles change -2% YoY. Normal
Manipulation Score
M-Score = -2.69 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor FOLD continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25